Advance Basal Cell Carcinoma Market - Forecast(2025 - 2031)

Advance Basal Cell Carcinoma Market Overview

Advance Basal Cell Carcinoma Market Size is estimated to reach $9.1 billion by 2027. Furthermore, it is poised to grow at a CAGR of 8.7% over the forecast period of 2022-2027. Basal Cell Carcinoma is the most common type of skin cancer caused by uncontrolled and abnormal growth in the basal cell or lower epidermis. It does not spread to other parts of the body, but it may go deep into the bone. It looks like an open sore, with pink growths, and red patches and scars which can be caused by intense exposure to sun or ultra-violate rays and formed lesions. It mostly affects the head, face scalp, hand, and neck areas. It is mostly found in elderly and fair-skinned individuals. It can be cured with surgical, destructive, and therapeutic treatment. In complicated cases where surgery is not sufficient radiation therapy or hedgehog inhibitors therapy is used to treat such cases. If basal cell carcinoma is not diagnosed and not treated on time, it goes to an advance level. It became more challenging to treat hence its size location, invasiveness, and extent. An individual suffering from basal cell carcinoma comes under two categories, one who delayed treatment advance basal cell carcinoma and another is reoccur with basal cell carcinoma after treatment. The American Cancer Society highly advises that people between the ages of 20 and 40 have a dermatologic check-up every three years, and people above the age of 40 should have one every year. As per NCBI analysis, carcinoma reoccurs in people who had a history of eczema, and people who were exposed to a high dose of UV light in their 20 to 30s. One whose original carcinoma is lagers than 2 centimeters, and one whose carcinoma is several layers deep in the skin as per Moffitt Cancer Center. In recent years, the market has grown owing to rising incidences of Basal cell carcinoma among the senior population, changing lifestyles of the urban population residing in developed countries, and improved awareness about the disease's recurrence rate and progression which helps to boost Advance Basal Cell Carcinoma Market over the forecast period 2022 – 2027.

Advance Basal Cell Carcinoma Market Report Coverage

The report: “Advance Basal Cell Carcinoma Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Advance Basal Cell Carcinoma Market.

By Disease Indication: Locally advanced basal cell carcinoma, and Metastatic advance basal cell carcinoma and Others.
By Treatment Type: Surgery (Surgical Excision, Electrodessication & Cutterage ED&C, Moh's Surgery, Cryosurgery), Drugs (tropical Treatment, Advanced Medication, and others) Others (Radiation Therapy, Photodynamic Therapy PDT, Laser Therapy)
By End Users: Hospitals, Research Institutes, Cancer Diagnostic Centers, Ambulatory Surgical Centers, Retail Pharmacies and Others.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

• Geographically, North America held a dominant market share in the year 2021, owing to advanced health infrastructure in countries like the United States and Canada.
• Growing rates of Advance Basal cell carcinoma among the senior population, changing lifestyles of the urban population living in developed countries, and improved awareness of the disease's recurrence rate and progressiveness have all contributed to the market's significant growth.
• However, the Advance Basal Cell Carcinoma Industry is expected to be hampered by delays in accessing medical care, a lack of knowledge among patients, and the high cost of certain treatments limiting market growth over the forecast period 2022-2027.
• A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Advance Basal Cell Carcinoma Market Report.

Advance Basal Cell Carcinoma Market Segmentation Analysis- By Treatment Type

Advance Basal Cell Carcinoma Market based on treatment type can be further segmented into Surgery (Surgical Excision, Electrodessication & Cutterage ED&C, Moh's Surgery, Cryosurgery), Drugs (tropical Treatment, Advanced Medication, and others) Others (Radiation Therapy, Photodynamic Therapy PDT, Laser Therapy). The surgery segment held a dominant market share in the year 2021, as it is the most common method to treat advanced basal cell carcinoma. The surgeon cut out the abnormal cells with the surrounding margin of healthy skin. After removal of abnormal carcinoma cells, the operated area is again inspected by microscope to confirm no cancers cell are left behind. It is commonly performed where surgery is easy like chest, back, hands and feet. It is preferred due to the low reoccurrence rate of basal carcinoma, maximum cure rates, and top cosmetics results. 

However, the Drug segment is estimated to grow with the fastest CAGR rate of 9.6% over the forecast period 2022-2027. Owing to their advantages of cosmetic outcome which have been repeatedly shown to be superior to cryotherapy, and hence, recommended as a treatment of choice for patients with multiple superficial or thin nodular BCCs, particularly if located at cosmetically important locations, thereby, enhancing the segment over the forecast period 2022-2027.

Advance Basal Cell Carcinoma Market Segmentation Analysis- By End Users

Advance Basal Cell Carcinoma Market based on end users can be further segmented into Hospitals, Research Institutes, Cancer Diagnostic Centers, Ambulatory Surgical Centers, and Others. The Hospital segment held a dominant market share in the year 2021 and is estimated to grow with the fastest CAGR rate of 9.9% over the forecast period 2022-2027. This is owing to the patient with advanced basal cell carcinoma getting diagnosed in the hospital. Also, at hospitals patients get expert advice from skincare specialists and customizable treatment plans basis on the severity of cancer. The hospitals provide renowned experts in skin cancer and dermatologic surgery for patients diagnosed with basal cell carcinoma, who construct a specific treatment plan for patients that can include a variety of alternatives that have been demonstrated to be very effective in treating BCC. Among the procedures are Mohs micrographic surgery, cryosurgery, electrodesiccation, and curettage. As a result, individuals are drawn to hospital treatment in large numbers. The demand for this segment has risen as a result of this.

Advance Basal Cell Carcinoma Market Segmentation Analysis- By Geography

The Advance Basal Cell Carcinoma Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 33% in the year 2021. Owing to advanced health care infrastructure, technological advancement, better health care facilities for early diagnosis of advance basal cell carcinoma, increasing awareness among people, and research and developments by key market players. Research estimate that more than 3 million Americans are affected each year by nonmelanoma skin cancer (NMSC), which includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). In the United States, 197,700 new cases of melanoma will be diagnosed in 2022, with 97,920 non-invasive (in situ) and 99,780 invasive cases. Such an increase in advance basal cell carcinoma supports the market growth of the Advance Basal Cell Market in North America.

Furthermore, the Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. According to better healthcare infrastructure and the fastest increasing old age population in the Asia-Pacific region. According to ‘Cancer Journal for Clinicians In 2040, there are estimated to be 28.4 million cancer cases worldwide. The rate of Advance Basal Cell Cancer per 100000 populations is (0.32 - 6.4 in Chinese), (0.7- 1.4 in Asian Indians), (1-2 in African Americans), and 6 in New Zealand. Also, elderly peoples are prone to advance basal cell carcinoma and in Asia pacific about Nearly about 1.3 billion people 60 years and above will live in Asia-Pacific, according to the Economic and Social Commission for Asia and the Pacific, hence, driving the Advance Basal Cell Carcinoma’s regional expansion.

Advance Basal Cell Carcinoma Market Drivers

Increased Incidence of Epidermal Cancers to Drive Product Demand

The rising frequency of basal cell carcinoma, increasing consumer awareness of the condition, and the presence of advantageous reimbursements scenarios in high prevalence regions are all helping to boost the market for basal cell carcinoma treatment. The increased prevalence of various dermatological malignancies, particularly non-melanoma skin cancers like basal cell carcinoma and squamous cell carcinoma, is having a significant impact on the need for basal cell carcinoma treatment all over the world. As the increasing elderly population increases the chances of basal cell carcinoma, according to ‘Cancer Journal for Clinicians In 2040, there are estimated to be 28.4 million cancer cases worldwide. As the increased rate of cancer and increase in awareness drives the market growth.

The Increase in Healthcare Expenditure and Increase Investment in Health-infrastructure Drives the Market Growth.

As increasing critical diseases like CVD, cancer, and neurological diseases around the world, many more countries, and healthcare companies around the world are focusing on better healthcare infrastructure and also on research and developments for better diagnosis and treatment. As per the Niti Ayog's report Foreign Direct Investment (FDI) in India is raised up to USD $50 billion in the years 2019-2020. India also allowed 100% FDI in the healthcare sector which helps to strengthen the healthcare industry in India. Innovation in the healthcare industry raised $ 44 billion globally in 2021 as per start-up health research insight. Furthermore, CRISPR, artificial intelligence, telemedicine, the Infinium Assay, cryo-electron microscopy, and robotic surgery are among the technologies and breakthroughs that are aiding in the fight against cancer. Such innovation and investment in the healthcare sector are driving Advance Basal Cell Carcinoma Market.

Advance Basal Cell Carcinoma Market Challenges

High Cost of Treatment and Lack of Awareness Limits The Market Growth.

Also, the high likelihood of basal cell carcinoma going undiagnosed in the coming years may stymie the global market for basal cell carcinoma treatment. According to Asia-Pacific Frontline Healthcare Report-2020, Healthcare expenditures are increasing at a quicker rate than real earnings, with surges of 3.3 times and 7.8 times in Australia and Singapore, respectively. Out-of-pocket medical expenditures are unaffordable for 57%, while private insurance prices are out of control for 42%. Such a high cost of treatment in emerging economies, as well as a lack of awareness, may limit the market's growth over the forecast period.

Advance Basal Cell Carcinoma Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Advance Basal Cell Carcinoma Market. The top 10- Advance Basal Cell Carcinoma Market companies are-

1. Allergan, Inc
2. Novartis AG
3. Taro Pharmaceutical Industries Ltd.
4. Perrigo Company plc
5. Valeant Pharmaceuticals International Inc.
6. Apotex Inc.
7. Provectus Biopharmaceuticals, Inc.
8. Sandoz AG
9. Strides Arcolab Ltd.
10. TOLMAR Pharmaceuticals, Inc

Recent Developments

• In February 2022, Novartis AG- one of the largest manufacturers of pharmaceuticals, announced the grant of the European Gilenya (fingolimod) 0.5mg daily dose patent. Fingolimod is used to treat the relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
• In February 2022, Taro Pharmaceutical Industries Ltd- a multi-national, science-based pharmaceutical company, announced the completion of the acquisition of Alchemee (former The Proactive Company TPC) from Galderma. This acquisition includes business and assets of Alchemee all over the world including the Proactive brand.
• In September 2021, Perrigo Company plc announced acquired leading consumer self-care company HRA pharma for $ 2.1billion. HRA is over a counter (OTC) company with three categories of self-care brands blister care (Compeed), Women’s health (ellaOne), and Scar care (Mederma).

Relevant Titles

Cancer Biomarkers Market - Industry Analysis, Market Size, Share, Trends, Growth And Forecast 2022 - 2027

Report Code: HCR 0194

Cancer Diagnostics Market - Forecast(2022 - 2027)

Report Code: HCR 0195

Cancer Hormone Therapy Market - Forecast(2022 - 2027)

Report Code: HCR 0196

For more Lifesciences and Healthcare Market reports, please click here